Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Retatrutide GLP-3 Vial All Retatrutide GLP-3 research Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine, The Lancet, and Nature Medicine, including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants
For 50 cents more
The GLP-1 Gold Rush: What Weight-Loss Drug Marketing Reveals About the Future of Pharma Media The surge in GLP-1 weight-loss drugs has reshaped the healthcare landscape almost overnight
Modulates expression of collagen, decorin, elastin and matrix-metalloproteinase genes in dermal fibroblast cultures
Weight loss happens gradually, with most significant results appearing between months six and 12
US$ 22.65
US$ 25.00
US$ 28.39
US$ 27.62
